Introduction
The transition from a prepubertal state to sexual maturity occurs through a complex series of biological transformations known as puberty. This transition plays a critical role in child development, and pubertal timing has significant social and clinical implications [1] . Over the past 15 years, a trend toward earlier onset of puberty has been documented, particularly in girls [2] . This trend has been accompanied by increased rates of childhood obesity and declining physical activity levels, especially in more developed countries [3] .
Studies in perinatally HIV-infected (PHIV) children have shown delayed pubertal onset [4] [5] [6] [7] and some evidence of delays in attaining sexual maturity [7] compared with HIV-uninfected peers, with greater delay among those with greater disease severity [6, 7] . In particular, we previously reported that the adjusted mean age at pubertal onset was delayed by 6 months in PHIVas compared with perinatally HIV-exposed uninfected (PHEU) youths, and by 4-13 additional months in PHIV youths with lower CD4 þ T-lymphocyte percentages (<15%) or higher HIV viral loads (above 10 000 copies/ml) [6] . The biological pathways through which perinatal HIV infection affects the timing of pubertal onset and sexual maturity are mostly unknown, limiting effective interventions for infected youths. As pubertal delay is known to correlate with poor growth in other populations, we hypothesized that growth deficits during late childhood may mediate an association between perinatal HIV infection and delayed sexual maturation [7] [8] [9] [10] [11] [12] [13] [14] .
Using data from two longitudinal cohort studies of children born to HIV-infected mothers, we evaluated the effect of perinatal HIV infection on the age at sexual maturity and employed novel approaches within a mediation analysis framework to investigate the proportion of this effect that might be explained by deficient growth.
Methods

Study population
The current study included youths from two US-based longitudinal cohort studies of children born to HIVinfected mothers, the 219/219C study of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and the Adolescent Master Protocol (AMP) study of the Pediatric HIV/AIDS Cohort Study (PHACS) Network. The 219/219C study enrolled PHIV and PHEU children at more than 80 sites in the United States between 1993 and 2007 and was designed to evaluate long-term effects of HIV infection and perinatal HIV exposure [6] . AMP was established in 2007 and is a smaller, ongoing cohort study of PHIVand PHEU children who were 7-16 years old at entry [12] . Approximately 70% of AMP youths previously participated in the 219/219C study. Both studies were approved by Institutional Review Boards at Harvard T.H. Chan School of Public Health and at all clinical research sites, and written informed consent was obtained from each parent or legal guardian, with assent from children as appropriate.
Children had scheduled visits every 3 months in the 219/219C study and every 6 (until 2010) or 12 months (2010 and later) in the AMP study. Medical histories and health status were ascertained at each study visit through chart reviews, physical examinations, and laboratory evaluations. Race and ethnicity were self-reported at entry and categorized as white non-Hispanic, black nonHispanic, Hispanic, or 'other'. For the current analysis, we excluded children without a study visit after the age of 7 years and children who were at later stages of sexual development (Tanner stages 3-5) at their first study visit, yielding a final study population of 2539 children (1253 girls and 1286 boys). Among these, we considered study visits occurring after 7 years through 20 years of age.
Growth and sexual maturity assessments Height and weight measurements and pubertal staging assessments were recorded at each study visit. Pubertal staging was assessed by visual inspection by study clinicians of breast development and pubic hair in girls and genitalia and pubic hair in boys, according to the criteria of Tanner and Whitehouse, with stages ranging from 1 (prepubertal) to 5 (mature) [15] .
Statistical methods
For each participant, the date of the first pubertal assessment at age 7 years or older was used to define the start of follow-up. Measurements of height and weight were used to calculate age-adjusted and sex-adjusted Z-scores for height and BMI according to growth standards of the Centers for Disease Control and Prevention [16] .
Interval-censored approaches for survival outcomes were used to account for the fact that sexual maturity may occur between study visits rather than on a specific study visit date; this approach also allowed for right-censored outcomes, to reflect situations in which sexual maturity had not yet occurred by the last study visit. Intervalcensored models were fit using accelerated failure time (AFT) models under a normal distribution assumption for age at sexual maturity [6, 12, 17] . We first estimated the mean age [95% confidence interval (CI)] at sexual maturity separately for each pubertal marker, by HIV infection status, race/ethnicity, and birth cohort. We also evaluated the mean age (95% CI) for each of the four puberty markers by HIV infection status adjusted for race/ethnicity and birth cohort. This final model was replicated in two sensitivity analyses to assess whether results were influenced by the unbalanced distribution of birth years between HIV-infected and uninfected children. First, we restricted the sample to those children born after 1993, thus excluding those categories with a limited number of PHEU children. Next, we repeated the analysis by randomly selecting a sample of children born after 1993 matched for birth cohort. Adjusted mean ages at menarche were also calculated by HIV status among the subset of girls with this information available; an AFT model with an assumed normal distribution was used accounting for right censoring for girls not reaching menarche by their latest assessment.
Mediation analysis was conducted to partition the total effect of HIV infection at birth on the age at sexual maturity into a direct effect of HIV infection, not acting through height and BMI Z-scores, and an indirect effect acting through height and BMI Z-scores (mediators). We hypothesized that some proportion of the effect of HIV infection on sexual maturity might be explained by effects of deficient height experienced by PHIV children. Mediation analysis in this context requires modeling age at maturity as a function of HIV infection, repeating this model further adjusting for the mediator(s), and separately modeling the mediators as a function of HIV infection [18, 19] . In this study, we applied an extension of the method to jointly evaluate the effect of two mediators (height and BMI Z-scores) [20] . Coefficients corresponding to the HIV infection effects without and with adjustment for the mediators were used to estimate, respectively, the total effect and direct effect of HIV infection, using interval-censored methods as previously described. The indirect effects, acting through differences in growth, were calculated by fitting separate models for the height and BMI Z-score mediators and multiplying the HIV coefficients from these models with the HIV coefficient from the mediator-adjusted maturity model [18, 21, 22] . We present results in terms of proportion mediated, calculated for each mediator as the ratio between the indirect and the total effect. Because our mediators were continuous, linear models were utilized to model the HIV-mediator relationships for height and BMI Z-scores. All statistical models were further adjusted for race/ ethnicity and birth cohort. Possible interactions of the mediators with each other and with HIV were also explored by extending the multiple mediators approach proposed by Vanderweele and Vansteelandt [20] . However, no evidence of such interactions were detected, and all presented results omit interaction terms.
Because height and BMI change over time, their contribution in the causal pathway from HIV infection to sexual maturity might vary by age. Our repeated measures of height and BMI allowed exploration of how the percent mediated effect varied at different time points in adolescence. For each sexual maturity marker, mediation analysis was replicated on the basis of height and BMI Z-scores at four different ages (each in a separate model, as illustrated in Fig. 1 ): at the first study visit and at ages 10, 11, and 12 years. To allow comparison between the four scenarios, the mediation models were restricted to $500 children of each sex who had a first study visit before age 10 years, at least one visit per year between 10 and 12 years, and experienced sexual maturity after 12 years. When multiple visits per year were available, the visit closest to the participant's birthday was used. All statistical analyses were performed with the R package survreg (R Foundation for Statistical Computing, Vienna, Austria). Statistical tests were two-tailed, and P values less than 0.05 were considered statistically significant.
Results
Characteristics of the study population at baseline (first visit at 7 years or older) are presented by HIV infection Sexual maturity in perinatally HIV-infected youths Bellavia et al. 1335 status and sex in Table 1 . The 453 PHEU children were on average younger and had greater height and BMI Z-scores than the 2086 PHIV youths. The distribution of sex and race was similar between PHIV and PHEU youths, with high percentages of black non-Hispanic and Hispanic youths in both groups.
During a median follow-up of 4 years, 338 boys (27%) and 385 girls (31%) achieved sexual maturity according to at least one pubertal marker. Mean ages at sexual maturity were 15.5 (95% CI: 14.5, 16.5) and 15.5 years (14.4, 16.6) for breast and pubic hair among PHIV girls, and 15.9 years for genitalia (14.8, 17.1), and 15.8 years for pubic hair (14.7, 16.9) among PHIV boys (Table 2) .
Compared with PHEU youths, PHIV children showed consistently later attainment of sexual maturity by $6 months for all puberty indicators (Table 2 ). These differences attained statistical significance only for breast maturity in women, but exhibited consistent trends for other maturity indicators. In the overall sample, race was significantly associated with age at sexual maturity only among girls, with black non-Hispanic girls experiencing maturity 5 months earlier on average than white nonHispanic girls (Table 2) . Among black non-Hispanic youths, the estimated mean ages at sexual maturity among PHEU youths were 14.2 (13.5, 14.9) and 14.4 (13.7, 15.1) years for breast and pubic hair among girls, respectively, and 15.1 years (14.3, 15.9) for both markers for boys. A temporal trend was also documented, with a significant decrease in mean age for younger birth cohorts (i.e., born more recently) for all maturity markers. This trend remained significant after adjusting for HIV infection status and race/ethnicity. After adjustment for race/ethnicity and birth cohort, the mean age at sexual maturity was consistently older for PHIV than for PHEU youths, but significant differences were no longer observed (Table 2 ). Our two sensitivity analyses (excluding children born before 1993 and matching by birth cohort) showed negligible differences from our original findings, suggesting minimal influence of the imbalance in birth years between HIV-infected and uninfected children (Supplementary Tables S1 and S2 , http://links.lww.com/QAD/B78). The mean age at menarche in a subset of 390 girls with available information was 12.5 years for PHIV girls and 12.0 years for PHEU girls, reflecting a delay of 5 months in both the unadjusted (4.9 months; 95% CI: 1.3, 8.5) and adjusted models (5.2 months; 95% CI: 1.4, 9.1). Table 3 shows the effect of perinatal HIV infection status on growth measures in a subsample of the study population with annual visits between ages 9 and 12 years, stratified by sex. After adjusting for race/ ethnicity and birth cohort, PHIV youths had significantly lower height Z-scores at all ages evaluated, with the largest difference at age 11 years for girls and age 12 years for boys. Although BMI Z-scores were also lower among PHIV than PHEU youths at all ages, differences were NS. Results from the mediation models are presented in Fig. 2 . Growth as reflected by height and BMI Z-scores mediated a large proportion of the total effect of HIV infection on age at sexual maturity for all pubertal markers, with considerable differences between boys and girls. Among women, both BMI and height Z-scores played a substantial role, with the strongest association at age 11 years: 74% of total effect was mediated by the two growth measures for both breast and pubic hair maturity. Among men, the proportion mediated by growth progressively increased with age, explaining up to 53% of the lag in genitalia maturation and 98% of the lag in pubic hair maturation at age 12 years. However, in contrast to girls, indirect effects were entirely attributable to height Z-score, with no evidence that BMI Z-score mediated the effect of HIV infection on timing of sexual maturity.
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Discussion
The current study is one of the first to estimate age at sexual maturity among youths with perinatal HIV infection and to evaluate differences between infected and uninfected youths within the context of a large prospectively followed cohort. We observed a delay in the age at sexual maturity among PHIV youths compared with PHEU youths. Moreover, we found that this effect was partly mediated by deficient height experienced by PHIV children. The impact of growth differed by sex, with both lower height and BMI among girls contributing to later age at maturity, whereas only lower height appeared to mediate effects of HIV on timing of sexual maturity among boys. The contribution of growth as a mediator of the effect of HIV on sexual maturity varied with age, with the strongest contribution at age 11 years for girls and age 12 years for boys. This finding is not unexpected given the typically earlier pubertal onset of girls as compared with boys [6] .
Although previous studies addressed differences between PHIV and PHEU children in timing of pubertal onset [4] [5] [6] [7] , few studies have evaluated sexual maturity among PHIV youths [7] . The shift in mean age at maturity of approximately 6 months in PHIV as compared with PHEU adolescents is similar to that previously observed for age at pubertal onset [6] , suggesting that once pubertal onset has begun, the pace of pubertal progression remains similar in PHIV and PHEU youths.
Clinical effects of a shift of 6 months in the age at sexual maturity are anticipated to be subtle and may not reflect 'clinical delay' for most PHIV youths, but may nevertheless translate to a higher than expected percentage of PHIV youths with clinically delayed maturity. Based on age at Tanner stage 5 more than 2 SDs above sex-specific and race-specific means [23] , 9.9% of PHIV boys and 1338 AIDS 2017, Vol 31 No 9 Fig. 2 . Proportions of the total effect of perinatal HIV infection on the age at sexual maturity mediated by height Z-scores (dark gray) and BMI Z-scores (light gray) (indirect effect), according to four indicators of sexual maturity. Results were obtained by fitting mediation analysis models on $500 children of each sex (breast: n ¼ 491; female pubic hair: n ¼ 487; genitalia: n ¼ 522; male pubic hair: n ¼ 526) with assessments at all four time points, corresponding to the four panels of Fig. 1 . No significant results were observed in this analysis.
10.7% of PHIV girls met the criteria for clinically delayed sexual maturation, as compared with an expected 2.5% in the general US population. In addition, there may be other public health implications of alterations in timing of sexual maturity, including reduced self-esteem and decreased bone mineral density. Previous research has focused predominantly on associations of early puberty on adverse health outcomes [1, 24] , but recent findings have indicated associations of delayed puberty with increased risk of specific cancers. For example, Lope et al. [25] recently reported a 6% increase in risk of prostate cancer for each 1-year delay in pubertal onset in boys.
A recent African study of PHIV youths reported mean ages of 16.1 and 16.5 years for breast and pubic hair maturity in girls, respectively, and 16.9 and 16.8 years for genitalia and pubic hair maturity in boys, respectively [7] . These later mean ages at maturity than those we observed may be partially explained by greater height and weight deficits in HIV-infected children in Africa relative to those of the United States [26, 27] . Consistent with our findings of strong effects of growth on pubertal maturation, this African study found that lower height was associated with additional pubertal delays among HIV-infected boys and girls, and also observed effects of BMI on pubertal maturation only in girls [7, 14] . Other diseases known to affect growth in children, such as type 1 diabetes and cystic fibrosis, have also been shown to affect sexual maturation [28, 29] .
Growth delays in HIV-infected children, including those receiving combination antiretroviral treatment (ART), are common and not typically associated with growth hormone (GH) deficiency. However, low insulin-like growth factor 1 (IGF-1) levels may be present, possibly mediated by chronic inflammation causing increased production of cytokines or by undernutrition, either of which may lead to a state of GH resistance [30, 31] . Evidence also exists for concomitant GH and IGF-I resistance in association with HIV infection [32, 33] . In the current study, height had differential effects on genitalia and pubic hair maturation in boys; height explained about half of the HIV effect on genital maturation, but almost 100% of the effect on pubic hair. The pulsatile secretion of gonadotropin-releasing hormone triggers pituitary secretion of luteinizing hormone and follicle-stimulating hormone which, in boys, drive testicular growth and spermatogenesis, respectively [34, 35] . In contrast, the start of pubic hair maturation is linked to adrenal maturation (adrenarche), the exact hormonal controller of which is unknown. Thus, it is not entirely unexpected that the role linear growth plays in affecting subsequent maturity may vary between these two pathways.
Our analysis represents a novel approach for evaluating the contributions of both HIV infection and growth on timing of sexual maturity. Using recently developed mediation analysis frameworks, we were able to evaluate multiple mediators (height and BMI) and their interactions on age at maturity [18, 20] . Mediation analysis approaches for survival outcomes have only been recently developed and, to our knowledge, have not specifically been applied to interval-censored outcomes [19] . However, the framework of AFT models allows parametric models to be specified for the intervalcensored outcomes of interest, and identification of indirect and direct effects of the primary exposure of interest (in this case, perinatal HIV infection) follows directly from previous assertions [19] .
The large size of our cohort, longitudinal follow-up over almost 4 years, inclusion of an uninfected comparison group from a similar racial and socioeconomic background, and annual physician-assessed evaluations of pubertal staging are key strengths of our study; however, we recognize that our study has some limitations. Our observational cohort of perinatally infected youths represents a survivor cohort, particularly for youths born in the earliest years when effective antiretroviral therapy was not available. In addition, youths without HIV infection tended to be born in later years as a result of shifts in the HIV epidemic and improved management of HIV-infected pregnant women; thus, distinguishing trends over time within this subgroup is restricted to later birth cohorts. In addition, due to the generally younger age at study entry for PHEU youths, a much smaller percentage had been followed until an age at which sexual maturity would be expected, despite a similar duration of overall follow-up from study entry. Finally, the effect of HIV infection on timing of sexual maturity via its effect on growth may also be partially attributable to the previously demonstrated association of HIV with later pubertal onset, which in turn affects subsequent growth. Our approach evaluated the overall association between HIV infection and growth through multiple pathways, including alterations in the timing of pubertal onset.
To consider the role of growth measures at different ages while limiting the effects of selection bias, we restricted our mediation analysis to a smaller subset of youths with consistent annual follow-up measures, which reduced our power for detecting statistically significant associations. As such, results from the mediation analyses models should be interpreted with caution and need to be replicated in larger cohorts. Like all observational cohorts, there is also the potential for unmeasured confounding, but our findings were relatively robust after adjustment for race/ ethnicity and birth cohort. However, the presence of unmeasured confounders, especially of the mediatoroutcome associations, cannot be excluded and may limit the causal interpretation of our results [36] . The limited number of participants achieving maturity by the end of follow-up may also limit the interpretation of our results. However, these two prospective cohorts are characterized by a high retention rate, with less than 5% of study participants lost to follow-up each year [37] . Censoring was primarily due to study closure or administrative censoring and thus was unlikely to bias analysis results. Another possible limitation is the imbalance in age at baseline between PHIV and PHEU children, which might increase the risk of selection bias due to exclusion of a higher proportion of PHIV children who were sexually mature at baseline.
Finally, given the relatively limited number of youths who attained maturity during the course of the study, we were unable to address the impact of specific ART regimens or markers of immune status on timing of sexual maturity. The benefits of combination ART regimens have led to improvements in growth, at least in more developed countries, which may translate into reductions in previously observed delays in pubertal maturation. Future studies to evaluate the relationships between age of combination ART initiation (and specific ART regimens), height and BMI, and sexual maturation are warranted as more perinatally infected children transition to young adulthood.
In conclusion, PHIV youths experience delays in pubertal maturation that may have adverse long-term consequences, including reduced self-esteem and decreased bone mineral density, along with possible increased risks of some cancers [1, 24, 25, 35] . The deficient growth experienced by PHIV children was found to be an important contributor to this negative effect. Effects mediated through growth differed by growth measures (BMI vs. height) and sex and between markers of maturity for boys. The role of growth in altering pubertal development of PHIV children indicates a potential for interventions (including early ART) that should ideally be initiated prior to the adolescent growth spurt.
